NORGES: RATES PROBABLY AT CURRENT LEVEL QUITE SOME TIME

RATES MAY NEED TO BE ON HOLD LONGER THAN ENVISIONED: NORGES

MNI: NORGES BANK LEAVES RATES UNCHANGED AT 4.50%

MNI WATCH: CNB Seen Cutting 50Bps to 5.25%, Signal Slower Pace

MNI China Daily Summary: Tuesday, April 30

MNI BRIEF: China To Keep Tackling Risks In Real Estate, Debts

MNI: BAKER HUGHES US RIG COUNT 605; OIL RIGS 499; GAS RIGS 102

BoE Data Watch

RBA Data Watch

RPT-MNI: Canada Sticks To Fiscal Anchors, Spends Chunk Of Windfall

MNI BRIEF: Poilievre Calls QE 'Scam' And Would Limit BOC Remit

MNI: Growth Drag From Net Zero Carbon Goal Can Be Offset-OECD

© 1982-2023 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

Pre-market Equity Movers

CREDIT PRE-MARKET
Credit BulletsBulletHomepagemarkets-real-timeCredit

Big falls from competitor pharma's (Madrigal, Akero, 89Bio & Viking) who are developing therapies for non-alcoholic steatohepatitis (NAHS) (a liver disease) after Eli Lilly's positive results from its experimental drug Tirzepitide in Phase 2 trials - 74% of participants achieved absence of NASH vs. 13% in placebo. Equity vol in this space on the developments is not new, no credit from the four leading pre-market losses & none are SPX members.

71 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Big falls from competitor pharma's (Madrigal, Akero, 89Bio & Viking) who are developing therapies for non-alcoholic steatohepatitis (NAHS) (a liver disease) after Eli Lilly's positive results from its experimental drug Tirzepitide in Phase 2 trials - 74% of participants achieved absence of NASH vs. 13% in placebo. Equity vol in this space on the developments is not new, no credit from the four leading pre-market losses & none are SPX members.